Updated results from the KATHERINE trial showed that adjuvant T-DM1 provided a significant improvement in overall survival and no evidence of long-term safety issues.

HER2-overexpressing breast cancer Trastuzumab, in combination with an anthracycline- and taxane-containing chemotherapy regimen, has become the universally-accepted standard of care for high-risk ...

whether neoadjuvant chemotherapy was administered with trastuzumab alone or with an additional HER2-targeted agent, pathological nodal status at surgery, age cohorts, and race. However ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

She writes a regular blog on her experiences for the Warrington Guardian. Where is the time going? We’re already half way through January and Christmas seems a million miles away, but I hope everyone ...

In large, multicenter trials of trastuzumab as a single agent or in combination with chemotherapy as first-line or second-line therapy for metastatic breast cancer (MBC), response rates have ...

Phase 3 data support pyrotinib plus trastuzumab and docetaxel “as a well-established and effective treatment strategy,” according to Binghe Xu, MD.

In contrast, Herceptin/Perjeta administration needs ... Phesgo has been recommended by the CHMP for use in combination with chemotherapy in early HER2-positive breast cancer – pre- and post ...

And, in fact, this study showed that the additional palbociclib to this kind of treatment was able to significantly prolong PFS from the start of the maintenance treatment with a benefit in terms of ...